AKR1C2
protein-codingaldo-keto reductase family 1 member C2, the group of Aldo-keto reductases
Gene summary
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols using NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme binds bile acid with high affinity, and shows minimal 3-alpha-hydroxysteroid dehydrogenase activity. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Dec 2011]
- DDH2
- TDD
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~30.3 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0013664
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0013664
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0013664
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Endocrine; Genitourinary; Oncologic
Intervention: Genitourinary; Oncologic
Rationale: Surveillance and/or awareness of cancer risk, and preventive measures may be beneficial to reduce the risk of gonadal tumors
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to AKR1C2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001393392.1. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 10 | 10 | ||||
| missense | 4 | 44 | 2 | 1 | 51 | |
| nonsense | 1 | 1 | ||||
| start loss | 0 | |||||
| frameshift | 3 | 3 | ||||
| splice donor/acceptor (+/-2bp) | 1 | 1 | ||||
| Total | 4 | 1 | 48 | 12 | 1 | 66 |
Highest pathogenic variant AF is 0.000011773395
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001380321.1 | 9 | MANE Select | |
| Ensembl | ENSP00000370129.4 | 9 | MANE Select | |
| RefSeq | NP_001128713.1 | 4 | Standard | |
| RefSeq | NP_001307956.1 | 8 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Steroid hormone biosynthesis - Homo sapiens (human)
- Chemical carcinogenesis - Homo sapiens (human)
- Benzo(a)pyrene metabolism
- Metapathway biotransformation Phase I and II
- Prostaglandin Synthesis and Regulation
Biological Process
- prostaglandin metabolic process
- G protein-coupled receptor signaling pathway
- digestion
- steroid metabolic process
- positive regulation of cell population proliferation
Molecular Function
- alditol:NADP+ 1-oxidoreductase activity
- alcohol dehydrogenase (NADP+) activity
- steroid dehydrogenase activity
- oxidoreductase activity
- oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor
Cellular Component
- cytoplasm
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000380753
- Coding exons
- 9
- Length
- 30257
- Individuals with no LoFs
- 125516
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 231
- Defined
- 125747
- p
- 0.000919
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.873 | 176 | 146 | 1.20 | 0.00000713 | 2083 |
| Missense (PolyPhen) | 73 | 63.343 | 1.1524 | 904 | ||
| Synonymous | -1.87 | 77 | 58.8 | 1.31 | 0.00000306 | 610 |
| Loss of Function | 0.140 | 16 | 16.6 | 0.963 | 0.00000101 | 212 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00055 | 0.00055 | rare |
| Latino/Admixed American | 0.00052 | 0.00052 | rare |
| Ashkenazi Jewish | 0.0061 | 0.0061 | notable |
| East Asian | 0.0025 | 0.0024 | notable |
| Finnish | 0.000046 | 0.000046 | rare |
| European (Non-Finnish) | 0.00032 | 0.00032 | rare |
| South Asian | 0.0018 | 0.0018 | notable |
| Other | 0.00098 | 0.00098 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Works in concert with the 5-alpha/5-beta-steroid reductases to convert steroid hormones into the 3-alpha/5-alpha and 3-alpha/5-beta-tetrahydrosteroids. Catalyzes the inactivation of the most potent androgen 5-alpha-dihydrotestosterone (5-alpha- DHT) to 5-alpha-androstane-3-alpha,17-beta-diol (3-alpha-diol). Has a high bile-binding ability. {ECO:0000269|PubMed:15929998, ECO:0000269|PubMed:17034817, ECO:0000269|PubMed:17442338, ECO:0000269|PubMed:8573067}.;
Intolerance Scores
- LoFtool
- 0.916
- RVIS EVS
- -0.09
- RVIS percentile EVS
- 46.74
Essentials
- Essential (CRISPR)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.908
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |